All In Biotech

Drug Trial Radar · NCT06910358

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 183 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

183

Actual

Start

Apr 4, 2025

Primary completion

Sep 8, 2026

Study completion Sep 8, 2026

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
Apr 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants with EPP or XLP. * How PPIX concentration levels change from before bitopertin treatment to after 6 months of treatment. Researchers will compare bitopertin to a placebo look-alike substance that contains no drug. Participants will complete daily questionnaires and attend study visits for assessments.

Conditions

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)

Interventions

  • PlaceboDrug

    Oral dose, once a day for 24 weeks

  • DISC-1459Drug

    Oral dose, once a day for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Average monthly total time in sunlight on days without pain from a phototoxic reaction between 10:00 to 18:00 (10:00 AM to 6:00 PM) after 6 months (24 weeks) of treatmentTime frame: 24 weeks
  2. Percent change from baseline in whole-blood metal-free PPIX levels at 6 monthsTime frame: 24 weeks
  3. Safety and tolerability, as assessed by adverse events (AEs) and laboratory results, over the 6-month treatment periodTime frame: 24 weeks

Locations

27 sites in 12 countries. Site status is shown where the registry gives one.

  • Marvel Clinical Research

    Huntington Beach, California

  • University of California San Francisco

    San Francisco, California

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • MetroBoston Clinical Partners

    Boston, Massachusetts

  • Henry Ford Health System

    Detroit, Michigan

  • Mount Sinai Hospital

    New York, New York

  • Wake Forest University

    Winston-Salem, North Carolina

  • Remington-Davis Clinical Research

    Columbus, Ohio

  • University of Texas Medical Branch

    Galveston, Texas

  • University of Washington

    Seattle, Washington

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • UZ Leuven

    Leuven, Belgium

  • University of Alberta

    Edmonton, Alberta, Canada

  • CHU de Nantes - Hôtel Dieu, Service de dermatologie

    Nantes, France, France

  • Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard

    Paris, France, France

  • Charité - Universitätsmedizin Berlin, Institute of Allergology

    Berlin, Germany, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Saxony, Germany

  • Children's Health Ireland (CHI)

    Dublin, Ireland

  • Instituto Dermatologico San Gallicano Istituti Fisioterapici Ospitalieri IRCCS

    Roma, Italy

  • Erasmus MC

    Rotterdam, The Netherlands, Netherlands

  • Hospital Clinic de Barcelona

    Barcelona, Spain, Spain

  • Karolinska University Hospital

    Stockholm, Sweden, Sweden

  • Photobiology Unit, Salford Royal Hospital

    Salford, United Kingdom

  • Guy's and St Thomas' NHS Foundation Trust

    London, England, United Kingdom

  • Clinical Research Centre, Ninewells Hospital & Medical School , NHS Tayside

    Dundee, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.